Article Details
Retrieved on: 2020-01-03 17:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Roth Capital reaffirmed their buy rating on shares of Vascular Biogenics (NASDAQ:VBLT) in a research report released on Thursday, Zacks.com ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here